<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04971447</url>
  </required_header>
  <id_info>
    <org_study_id>21.03.30.69624</org_study_id>
    <nct_id>NCT04971447</nct_id>
  </id_info>
  <brief_title>Extracellular Vesicles and Endothelial Function in Transgender Subjects</brief_title>
  <acronym>Evinge</acronym>
  <official_title>Effects of Plasma Extracellular Vesicles on Endothelial Function in Transgender Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiovascular diseases are the leading cause of mortality. In women, the prevalence of&#xD;
      cardiovascular diseases is lower and the presentation of coronary events often atypical. The&#xD;
      lack of evidence is related in part to the methodology of studies not considering sex as an&#xD;
      essential biological variable. Hormonal treatment is prescribed in transgender subjects to&#xD;
      promote the development of sexual characteristics of the desired sex. Early cardiovascular&#xD;
      effects of hormonal treatment have been reported in transgender men, while long-term&#xD;
      mortality is higher in transgender women. The aim of this project is to study the effects of&#xD;
      gender affirming hormonal treatment on arterial stiffness in young transgender subjects&#xD;
      followed at the University Hospital of Nancy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pulse wave velocity</measure>
    <time_frame>24 months</time_frame>
    <description>measurement of arterial stiffness</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Transgenderism</condition>
  <arm_group>
    <arm_group_label>Group: transgender men</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Groupe: control cis-gender women</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group: transgender women</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Groupe: control cis-gender men</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gender affirming hormonal treatment in transgender men</intervention_name>
    <description>testosterone enanthate</description>
    <arm_group_label>Group: transgender men</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gender affirming hormonal treatment in transgender women</intervention_name>
    <description>GnRH agonists + estrogen</description>
    <arm_group_label>Group: transgender women</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Trasgender subject demanding gender affirming hormonal therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous hormonal therapy&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Chronic disease&#xD;
&#xD;
          -  Cancer&#xD;
&#xD;
          -  Obesity&#xD;
&#xD;
          -  Drug abuse&#xD;
&#xD;
          -  Alcohol&#xD;
&#xD;
          -  Tabac&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>yes</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 12, 2021</study_first_submitted>
  <study_first_submitted_qc>July 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2021</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>transgender persons</keyword>
  <keyword>hormonal therapy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

